Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 31Head & Neck 1Classical hematology 1Breast 1

Conditions

Leukemia, Myelomonocytic, Chronic 2Leukemia 2Anemia, Refractory, with Excess of Blasts 2Anemia 2beta-Thalassemia 1Thrombocytopenia 1Thalassemia 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neutropenia 1Myelodysplastic Syndromes 1Multiple Myeloma 1Fatigue 1Anemia, Sickle Cell 1Anemia, Refractory 1

Interventions

olaparib 2Epoetin Alfa 2Darbepoetin alfa 2Carboplatin 2venetoclax 1trametinib 1talazoparib 1ruxolitinib 1regorafenib 1ponatinib 1pertuzumab 1pembrolizumab 1palbociclib 1neratinib 1lorlatinib 1lenvatinib 1idelalisib 1enzalutamide 1entrectinib 1enasidenib 1durvalumab 1dehydroftorafur 1darolutamide 1dacomitinib 1dabrafenib 1copanlisib 1cobimetinib 1cabozantinib 1cabazitaxel 1bicalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Dexamethasone × Classical hematology × Clear all
NCT00060398 2023-06-15

Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer

Eastern Cooperative Oncology Group

Phase 3 Completed
282 enrolled
Classical hematologyGenitourinary

Anemia, Fatigue, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡